Former UK Biobank FInancial Director takes on the role at IXICO on 29 April 2019
IXICO has announced the appointment of Grant Nash as its Chief Financial Officer. A UK biotechnology company, IXICO provides neuroimaging services to biopharmaceutical firms conducting clinical trials. Grant will join the company on 29 April 2019 and it is anticipated that he will join the board in due course.
Grant joins IXICO from the UK Biobank, a national and international health research data resource, where he has been Finance Director since 2014. While with the UK Biobank, Nash was also responsible for the UK Biocentre, which provides biomedical sample processing and archiving logistics to large-scale research studies.
He was involved in separate fundraisings to raise more than £140 million for a variety of research and development projects. Prior to his time with the UK Biobank, Grant spent 10 years with Evotec AG, latterly as Senior Vice President of Finance, where he was responsible for the finance, IT, procurement facilities and logistics functions.
Evotec AG is a drug discovery business which reached 600 employees and sales of approximately €100 million during his tenure. Nash qualified as a Chartered Accountant with PwC.
Conor Woolfson, who assumed the role of interim Head of Finance in December 2018, will continue to perform these duties prior to Grant’s appointment, at which time he will then continue in his role of Group Financial Controller, reporting to Nash.
Giulio Cerroni, Chief Executive of IXICO, said: "I am delighted to welcome Grant to the company and I look forward to him bringing his financial leadership skills and experience in the sector to IXICO. I would also like to thank Conor Woolfson, who in addition to his responsibilities as Group Financial Controller, stepped into the role of interim Head of Finance in December.
“We are at an exciting stage of the company’s development, and Grant’s business experience in international commercial and large-scale research and development organisations will assist the Board and management team in delivering against our strategic objectives."